Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial

Tahir H, Mease PJ, Kavanaugh A, Reimold A, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Rheumatology Oxford University Press

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: 151-151

Conference Proceedings Title: RHEUMATOLOGY

Event location: Birmingham GB

DOI: 10.1093/rheumatology/kez107.074

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Dallas VA Medical Center US United States (USA) (US) Hasselt University / Universiteit Hasselt BE Belgium (BE) Swedish Medical Center US United States (USA) (US) Barts Health NHS Trust GB United Kingdom (GB) University of California, San Diego US United States (USA) (US) Novartis AG CH Switzerland (CH)

How to cite

APA:

Tahir, H., Mease, P.J., Kavanaugh, A., Reimold, A., Rech, J., Hall, S.,... Mpofu, S. (2019). Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial. In RHEUMATOLOGY (pp. 151-151). Birmingham, GB: OXFORD: OXFORD UNIV PRESS.

MLA:

Tahir, Hasan, et al. "Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial." Proceedings of the Annual Conference of the British-Soceity-for-Rheumatology, Birmingham OXFORD: OXFORD UNIV PRESS, 2019. 151-151.

BibTeX: Download